| Brenda Kaye Rudrow, RN | |
|
Route 1 Box 35 D, Boley, OK 74829 | |
| (918) 667-3367 | |
| (918) 667-3387 |
| Full Name | Brenda Kaye Rudrow |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Psychiatric/mental Health, Adult |
| Location | Route 1 Box 35 D, Boley, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508313636 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WP0809X | Registered Nurse - Psychiatric/mental Health, Adult | 90724 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brenda Kaye Rudrow, RN Route 1 Box 35 D, Boley, OK 74829 Ph: (918) 667-3367 | Brenda Kaye Rudrow, RN Route 1 Box 35 D, Boley, OK 74829 Ph: (918) 667-3367 |
News Archive
Leaders in medicine and dentistry will meet in Seattle July 28-29 to discuss a new approach in the fight against childhood dental disease: enlisting family physicians and pediatricians.
Investigators from Whitehead Institute, the Ragon Institute of MGH, MIT and Harvard and the Broad Institute of MIT and Harvard have used CRISPR-Cas9 gene-editing technology to identify three promising new targets for treatment of HIV infection.
The master gene called SRC-3 (steroid receptor coactivator 3) not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement - a key element of cancer spread or metastasis, said Baylor College of Medicine (www.bcm.edu) researchers and collaborators in a report that appears in the current issue of the journal Molecular Cell.
Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20 mg/mL), a generic version of Teva's Copaxone(R), a product indicated for the treatment of multiple sclerosis.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 2 days ago
Gaylen L. Newton, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Rr 1, Box 35d, Boley, OK 74829 Phone: 918-667-3367 Fax: 918-667-3387 | |
Kathy Putman, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Rr 1 Box 35d, Boley, OK 74829 Phone: 918-667-3367 | |
John Harbin Chelf, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Rt 1, Box 35d, Boley, OK 74829 Phone: 918-667-3367 Fax: 918-667-3387 | |
Mrs. Jennifer Dawn Cheatwood, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Rr 1,, Boley, OK 74829 Phone: 918-667-3367 Fax: 918-667-3387 | |
Mrs. Nola Larue Gibson, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2 Miles East Of Boley On Hwy 62, Boley, OK 74829 Phone: 918-667-3367 Fax: 918-667-3387 | |
Joyce Redding, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Rt.1 Box 35 D, Boley, OK 74829 Phone: 918-667-3367 Fax: 918-667-3387 |